Research programme: Anti-NLRP3-ASC antibodies - AC immune
Latest Information Update: 28 Jul 2024
At a glance
- Originator AC Immune
- Class Anti-inflammatories; Antibodies
- Mechanism of Action NLRP3 protein inhibitors; PYCARD protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in Switzerland
- 23 Mar 2021 Pharmacodynamics data from a preclinical studies in Neurodegenerative disorders released by AC Immune
- 23 Mar 2021 AC Immune plans in vivo proof-of-concept studies for Neurodegenerative disorders in the quarter IV of 2021